JY231 injection for relapsed B-cell blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment, JY231, for people with B-cell blood cancers that have come back or not responded to other treatments. It aims to see if this therapy can help when other options have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are up to 75 years old.
- You have a confirmed B-cell blood cancer (like lymphoma or leukemia).
- Your cancer cells have a protein called CD19 on their surface (a common marker).
- Your doctor expects you to live at least 3 more months.
- You are generally well enough to be up and about (ECOG score 0-3).
- Your liver, kidneys, heart, and lungs are working well enough for this treatment.
- You have enough blood cells (white cells, platelets, and hemoglobin) to safely undergo the procedure.
- You agree to use effective birth control if you could become pregnant or get someone pregnant.
- You have no active infections like hepatitis B, C, HIV, or syphilis.
- You have not had a previous treatment that targets CD19.
- You do not have other cancers that are active (except treated skin or cervical cancer).
- You do not have serious graft-versus-host disease (if you've had a stem cell transplant).
- You can give written consent and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection (JY231) for people with B-cell acute lymphoblastic leukemia (B-ALL) that has not responded well to treatment or has come back. It aims to see if the treatment can help reduce cancer cells in the bone marrow.
This trial tests an investigational drug called JY231 for people with active systemic lupus erythematosus (SLE) that is not well controlled with standard treatments. The goal is to see if JY231 can reduce lupus activity and improve symptoms.
This trial tests a new treatment, JY231, for people whose B-cell lymphoma has returned or stopped responding to previous therapies. It aims to see if JY231 can help shrink tumors or control the disease.
This trial tests a new injection called JY231 for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. The therapy targets a protein called CD19 on cancer cells, helping your immune system attack them.
This trial tests a new treatment called JY231 for people with a type of blood cancer (B-cell leukemia) that has come back or not responded to standard treatments. It aims to see if this therapy can help control the cancer.
This trial tests a new cell therapy called JY231 for people whose B-cell lymphoma or leukemia has come back or not responded to standard treatments. The therapy targets a protein on cancer cells called CD19 and may help your immune system fight the cancer.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.